FindTrial
Sign In

The ED95 of oliceridine for inhibiting cervical dilation during hysteroscopic surgery

The ED95 of oliceridine for inhibiting cervical dilation during hysteroscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107422
Enrollment
Unknown
Registered
2025-08-11
Start date
2025-08-11
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

1:0.02mg/kg oliceridine
2:0.03mg/kg oliceridine
3:0.04mg/kg oliceridine
4:0.05mg/kg oliceridine

Sponsors

Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: aged 18-64 years, body mass index (BMI) between 18-25, body weight between 45-60kg, ASA I-II level

Exclusion criteria

Exclusion criteria: history of allergy or contraindication to oliceridine, history of psychiatric disorders, comorbid severe cardiopulmonary diseases, use of analgesics within 24 hours before surgery, participation in other clinical studies, and other reasons deemed unsuitable for clinical research by the researchers.

Design outcomes

Primary

MeasureTime frame
move during cervical dilation;propofol Propofol dosage;Entropy index;—

Secondary

MeasureTime frame
Anesthesia induction time;Anesthesia recovery time;NRS score;Heart rate, blood pressure, respiration, and blood oxygen saturation;Satisfaction level;Flurbiprofen axetil or sufentanil;MOAA/S score;General patient information;—

Countries

China

Contacts

Public Contactxiaowei qian

Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China

qianxw@zju.edu.cn+86 150 8868 8422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026